Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, AZ Maastricht, The Netherlands.
Expert Rev Clin Immunol. 2010 Sep;6(5):713-20. doi: 10.1586/eci.10.67.
In the last decade, biological therapies have dramatically changed the treatment for rheumatoid arthritis (RA) in such a way that remission is currently an achievable goal. The armamentarium of therapeutic options for RA has recently been enriched with another approved anti-TNF-alpha agent, certolizumab pegol (CZP). This article reviews the trials conducted with CZP in RA, the Rheumatoid Arthritis PreventIon of structural Damage (RAPID 1 and 2) and the EFficAcy and Safety of cerTolizumab pegol - 4 Weekly dosAge in RheumatoiD arthritis (FAST4WARD). These trials have demonstrated that this new biological agent significantly improves the clinical signs and symptoms of RA, inhibits progression of structural damage, and improves physical function and quality of life in patients with active RA who have failed treatment with methotrexate. The safety profile of CZP is acceptable and similar to that of other anti-TNF-alpha agents.
在过去的十年中，生物疗法极大地改变了类风湿关节炎（RA）的治疗方式，使缓解成为目前可以实现的目标。RA 的治疗选择方案最近又增加了另一种被批准的抗 TNF-α 药物，即培塞利珠单抗（CZP）。本文回顾了 CZP 在 RA 中的临床试验，即类风湿关节炎结构损伤预防（RAPID 1 和 2）和培塞利珠单抗 - 4 周剂量在类风湿关节炎中的疗效和安全性（FAST4WARD）。这些试验表明，这种新型生物制剂可显著改善 RA 的临床体征和症状，抑制结构损伤的进展，并改善对甲氨蝶呤治疗反应不佳的活动性 RA 患者的身体功能和生活质量。CZP 的安全性特征是可以接受的，与其他抗 TNF-α 药物相似。
